The situation surrounding Moderna's (MRNA) mRNA-based flu vaccine has created a flurry of speculation, uncertainty, and is driving share market behaviour. The FDA initially declined to proceed with a review of the vaccine, citing issues with the application, which caused concern for both shareholders and industry experts. This decision sparked controversy about the potential risks for drug-makers in investing in vaccines. However, the FDA has since reversed its decision and agreed to review Moderna's flu vaccine. This unpredictable turnaround affected the company's valuation and share price momentum, as the vaccine is a critical part of Moderna's pipeline.
Separately, Moderna continues to advance in cancer therapy research, with promising results from their study of the Investigational Cancer Antigen Therapy mRNA-4359. Phase 1/2 Data on its use as a first line treatment in Melanoma showed an 83% response rate amongst patients. Additionally, the company is managing a patent dispute potentially costing up to $2.25 billion. As Moderna navigates these challenges, the price of the company's stock fluctuates, reinforcing speculation and assessment of the firm's valuation.
Moderna MRNA News Analytics from Tue, 05 Aug 2025 07:00:00 GMT to Sat, 18 Apr 2026 11:35:27 GMT - Rating 6 - Innovation 7 - Information 9 - Rumor -8
